Corx will go where the money is. Right now the shelf reserve provides a little insurance against a bully.
Hopefully something perks. I'm sure Corx would prefer one or two hot irons, rather than the myriad of early stage options for ampakine indication or finance.
No wonder our Corx shareholder fate is not predictable. The SA study is a cartoon of Corx reality.
Market Data 
Markets 
AI
